银屑病关节炎的治疗进展  

Progress in the Treatment of Psoriatic Arthritis

作　　者：闫旭[1] 石忠琪[1] 

机构地区：[1]天津市天津医院骨科,天津300211

出　　处：《医学综述》2013年第20期3750-3753,共4页Medical Recapitulate

摘　　要：银屑病患者10%～30%会出现自身免疫性炎性关节炎,通常称为银屑病关节炎（PsA）.其主要治疗方法是药物治疗,包括非甾体消炎药、糖皮质激素以及改善病情类抗风湿药（DMARDs）,其中甲氨蝶呤最为常用.目前对生物制剂的研究较多,最常用的为肿瘤坏死因子α抑制剂.针对PsA这种自身免疫性炎性疾病,粒细胞/单核细胞除滤输血是一种新的治疗方式,可以消除致病性白细胞.局部用药和物理疗法可以作为辅助治疗措施.如果出现关节变形和僵硬,可考虑外科治疗干预.Psoriatic arthritis（PsA） is a form of autoimmune inflammatory arthritis that occurs in approxi- mately 10% to 30% of individuals with psoriasis, depending on the popvlation studied. The various PsA pharmacotherapy approaches include non-sternidal antiinflammatory drugs（ NSAIDs）, low dose corticosternids and oral disease modifying anti-rheumatic drugs （DMARDs）. Methotrexate（MTX） is one of the most commonly used systemic medications in PsA. Biological agents currently approved for treatment of PsA ate the TNF- cdnhibitm＇s. Granulocyte/monocyte adsorption apheresis（GCAP） as cellular apheresis is now established as a rational therapeutic procedure in certain inflammatory and autoimmune diseases. Moreover the local agents and the physical therapy may be applied as adjuvant treatment for PsA. In the case of deformation and stiff- ness of joints, the surgery management can be considered.

关 键 词：银屑病关节炎 改善病情类抗风湿药 生物制剂 肿瘤坏死因子α抑制剂 

分 类 号：R684.3[医药卫生—骨科学]